详情页

当前位置：首页 > 详情页

Norvancomycin plasma concentration monitoring in hemodialysis patients with end stage kidney disease: A retrospective cohort study

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]Department of Pharmacy, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China. [2]Department of Clinical Laboratory, Hebei General Hospital, Shijiazhuang, China. [3]Department of Nephrology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.

出处：

DOI：

ISSN：

关键词： blood concentration monitoring end stage kidney disease hemodialysis infection norvancomycin

摘要：

Blood concentration monitoring plays an important role in the rational use of norvancomycin. However, the reference interval for the norvancomycin plasma concentration in the treatment of infections in hemodialysis patients with end stage kidney disease is undefined. To determine the safe and effective interval for the norvancomycin plasma trough concentration, 39 patients treated with hemodialysis and norvancomycin were analyzed retrospectively. The norvancomycin plasma concentration before hemodialysis was tested as the trough concentration. The associations of the norvancomycin trough concentration with efficacy and adverse reactions were evaluated. No norvancomycin concentration above 20 μg/mL was detected. The trough concentration, but not the dose, had a significant effect on the anti-infectious efficacy. Compared with the low norvancomycin trough concentration group (<9.30 μg/mL), the high concentration group (9.30-20.0 μg/mL) had improved efficacy (OR = 15.45, p < 0.01) with similar side effects (OR = 0.5417, p = 0.4069). It is beneficial to maintain the norvancomycin trough concentration at 9.30-20.0 μg/mL to achieve a good anti-infectious effect in hemodialysis patients with end stage kidney disease. Plasma concentration monitoring provides a data basis for the individual treatment of infections with norvancomycin in hemodialysis patients.© 2023 John Wiley & Sons Ltd.

基金：

语种：

PubmedID：

中科院分区：

出版当年[2023]版：

大类 | 4 区医学

小类 | 4 区药学

最新[2025]版：

大类 | 4 区医学

小类 | 4 区药学

第一作者：

第一作者机构： [1]Department of Pharmacy, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.

通讯作者：

通讯机构： [1]Department of Pharmacy, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China. [*1]Department of Pharmacy, The Fourth Hospital of Hebei Medical University, Health Road, Chang’an District, Shijiazhuang, Hebei, China.

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Early-onset type 2 diabetes: a high risk for end-stage kidney disease in patients with diabetic kidney disease [2]Alteration of Type I Collagen in the Radial Artery of Patients With End-Stage Renal Disease [3]去甲万古霉素封管预防重症患者中心静脉导管相关性感染的前瞻性随机对照研究 [4]血液透析中心医院感染的隐患及防控对策 [5]Toxic epidermal necrolysis complicated with mucormycosis infection [6]A Trial of Extending Hemodialysis Hours and Quality of Life [7]Reducing catheter-associated complications using 4% sodium citrate versus sodium heparin as a catheter lock solution [8]Norvancomycin for the treatment of central nervous system MRSA infections: A randomized controlled trial [9]Circulating miR-129-3p in combination with clinical factors predicts vascular calcification in hemodialysis patients [10]Prevalence of Chronic Kidney Disease-Mineral Bone Disorder in Hemodialysis Patients in Hebei, China